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Saitohin gene is not associated with Alzheimer's disease
Abstract
No evidence was found for an association of the non-synonymous polymorphism (Q7R) in
STH and Alzheimer's disease. This finding is in line with earlier studies showing no
association between MAPT and Alzheimer's disease.
SHORT REPORT
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Background: The deposition of tau protein in neurofibril-
lary tangles constitutes an important feature of many
neurodegenerative disorders, including Alzheimer’s dis-
ease. A polymorphic gene, saitohin (STH), nested within
the tau gene (microtubule associated protein tau, MAPT),
was recently identified and an association of a
non-synonymous polymorphism in STH with increased risk
for Alzheimer’s disease was suggested.
Objective and methods: To test the above hypothesis in
a case–control association study of two independent white
populations within Switzerland and Greece, comparing
genotype and allele frequencies from 225 Alzheimer’s dis-
ease patients and 144 healthy control subjects.
Results: No differences in allelic or genotypic distributions
between Alzheimer’s disease patients and controls was
found in the individual samples (Swiss/Greek) or in the
combined sample. Stratification for the presence of apoli-
poprotein E (APOE) e4 allele, sex, or age did not show
significant effects in the populations studied, nor was there
an effect on the age of onset.
Conclusions: No evidence was found for an association
of the non-synonymous polymorphism (Q7R) in STH and
Alzheimer’s disease. This finding is in line with earlier
studies showing no association between MAPT and
Alzheimer’s disease.
Recently, Conrad et al identified a gene nested within anintron of the tau gene (microtubule associated protein tau,MAPT), termed saitohin (STH).1 STH encodes for a 128
amino acid protein and is located in intron 9 of MAPT (2.5 kb
downstream of exon 9), a critical region for alternative splicing
of exon 10. Splicing in of exon 10 results in a protein with four
repeated microtubule binding domains (4R), in contrast to tau
without the exon 10, which displays only three microtubule
binding domains (3R). Distribution of STH mRNA in human
tissue is similar toMAPT, and high inmuscle, placenta, and fetal
and adult brain. To date, no specific function is known for STH.
However, putative phosphorylation sites for protein kinase C
and casein kinase II have been identified, which may be in line
with a combined function of STH and MAPT1; a non-
synonymous polymorphism (Q7R; CAA to CGA) was used to
carry out a case–control association study, which suggested
overrepresentation of the GG genotype, as well as the G allele, in
Alzheimer’s disease patients compared with controls.
Deposition of hyperphosphorylated tau in neurofibrillary
tangles is a central feature of Alzheimer’s disease,2 the most
common form of dementia in the elderly,3 and other neurode-
generative diseases, termed tauopathies, including frontotem-
poral dementia with Parkinsonism linked to chromosome 17
(FTDP-17), Pick’s disease, progressive supranuclear palsy, and
corticobasal degeneration.4 An imbalance of the different tau
isoforms is associated with the pathological changes in these
diseases. Familial forms of these tauopathies have been shown
to be caused by intronic and exonic mutations in the MAPT
gene5 6 affecting mainly the region around the alternatively
spliced exon 10. So far, studies examining potential associations
between Alzheimer’s disease and polymorphisms in MAPT
remain controversial.7–13 In this study we tested whether the
STH polymorphism was associated with risk for Alzheimer’s
disease, because first, STH and tau are in close vicinity, and sec-
ond, the allelic variance is positioned in a region involved in the
alternate splicing of MAPT, and thus also involving the regula-
tion of the ratio between 3R and 4R tau isoforms.
METHODS
We examined 225 patients with Alzheimer’s disease (accord-
ing to NINCDS-ADRDA criteria14) and 144 controls (tested
with CERAD battery and MMS15) in two white populations
(Swiss: 91 Alzheimer patients and 92 healthy controls; Greece:
134 Alzheimer patients and 52 controls) and undertook a
case–control association study for the non-synonymous poly-
morphism in STH (Q7R; CAA to CGA).
DNA was isolated from whole blood with a DNA extraction
kit (Qiagen, Hilden, Germany). Genotyping for STH was done
with the PSQTM 96 system (Pyrosequencing AB, Uppsala,
Sweden) (primer forward, GCC CCT GTA AAC TCT GAC CA;
primer reverse, GCT GAG GGT TCT GTC TCT GG, pyrosequenc-
ing primer, GTG AGG GTG GAG GC; for details see www.pyro-
sequencing.com). APOE genotypes were assessed using the
LightCyclerTM instrument (Roche Diagnostics Corporation,
Mannheim, Germany).16 Pipetting was done with a Genesis
Workstation 200/8 using Gemini v3.5 software (TECAN).
Statistics
For statistical analysis, we used Fisher’s exact test, Pearson’s χ2
(testing association), and the Kolmogorov–Smirnov test (test-
ing distributions between two groups). A probability (p) value
of < 0.05 was regarded as significant. Non-significant p values
are not shown. The study was approved by the local ethics
committee and informed consent was obtained before the
investigation.
RESULTS
The allelic distribution for STH in the combined sample was
78.59% (A) and 21.41% (G), and the genotypic distribution
was 61.8% (A/A), 33.6% (A/G), and 4.6% (G/G) (table 1, which
also includes single population data), following Hardy–
Weinberg equilibrium in both populations. Based on the
genotype frequencies reported by Conrad et al,1 our study had
a statistical power of more than 95% for α = 0.05. In contrast
to Conrad et al, we did not detect any significant difference in
the distribution of genotypes or alleles between the patients
with Alzheimer’s disease patients and the controls.
In previous studies associations of single nucleotide polymor-
phisms assigned to MAPT with Alzheimer’s disease were found
in APOE e4 carriers.7 11 We therefore stratified our sample for
APOE e4 carriers. As previously described, the APOE e4 allele
was significantly associated with the risk of Alzheimer’s disease
in our samples (Pearson’s χ2 = 20.44; p = 2×10−6). Stratification
in APOE e4 carriers and non-carriers did not reveal any signifi-
cant differences between the two groups, nor did stratification
for age (> 70 years or < 70 years at the age of onset) or sex.
Finally, to test whether STHmay act as a progressionmarker,we
determined the age of onset by Kaplan–Meier analysis, as well
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as the mean age of onset, and found no differences between the
genotypes (AA: mean age 72 years; 95% confidence interval
(CI), 71 to 73; AG: mean age 71 years; 95% CI, 69 to 73; GG:
mean age 73 years; 95% CI, 70 to 76).
DISCUSSION
Our findings are in line with two recent reports,17 18 both
showing no association between STH polymorphism and
Alzheimer’s disease. In addition, Verpillat and colleagues18
found a complete linkage of the Q genotype (A allele) with the
H1 tau haplotype in 91 patients with frontotemporal demen-
tia. They even concluded that the STH Q genotype could be
part of the extended H1 tau haplotype. In the controversial
discussion of the association between Alzheimer’s disease and
polymorphisms in MAPT,7–13 these three studies (Cook et al,
2002,17 Verpillat et al, 2002,18 and our own data) argue strongly
in favour of the absence of an association between variations
in MAPT and the risk of developing Alzheimer’s disease.
Conclusions
This study, like others, fails to support a significant association
between STH and Alzheimer’s disease. Stratification did not
reveal effects in subpopulations or special risk groups. The
promising gene saitohin (STH) (by its proposed function and
location) is not associated with the risk of Alzheimer’s disease.
Further analysis should be directed towards sporadic tauopa-
thies.
ACKNOWLEDGEMENT
We thank Mr Jay Tracy for careful reading and preparation of the
manuscipt, and Ms Esmeralda Garcia, Ms Christin Wilde, Ms Andrea
Hauer, and Ms Estelle Obrist for patient care and sampling. This work
was supported by grants of the National Center for Competence in
Research (NCCR) “Neuronal Plasticity and Repair”, the Swiss Science
National Foundation (32-65869.01), and the Roche Research Founda-
tion (22-2001).
. . . . . . . . . . . . . . . . . . . . .
Authors’ affiliations
J R Streffer, A Papassotiropoulos, P Kurosinski, A Signorell,
M A Wollmer, F Hörndli, J Bosset, J Götz, R M Nitsch, C Hock,
Division of Psychiatry Research, University of Zurich, Switzerland
M Tsolaki, V Iakovidou, Third Department of Neurology, Aristotle
University of Thessaloniki, Thessaloniki, Greece
Correspondence to: Dr Johannes Streffer, Division of Psychiatry Research,
University of Zürich, Lenggstrasse 31, 8029 Zürich, Switzerland;
streffer@bli.unizh.ch
Received 15 October 2002
Accepted 2 December 2002
REFERENCES
1 Conrad C, Vianna C, Freeman M, et al. A polymorphic gene nested
within an intron of the tau gene: implications for Alzheimer’s disease.
Proc Natl Acad Sci USA 2002;99:7751–6.
2 Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde.
Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin
1907;64:146–8.
3 Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s
disease in a community population of older persons. Higher than
previously reported. JAMA 1989;262:2551–6.
4 Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies.
Annu Rev Neurosci 2001;24:1121–59.
5 Gotz J. Tau and transgenic animal models. Brain Res Brain Res Rev
2001;35:266–86.
6 Hutton M, Lendon CL, Rizzu P, et al. Association of missense and
5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature
1998;393:702–5.
7 Baker M, Graff-Radford D, Wavrant DeVrieze F, et al. No association
between TAU haplotype and Alzheimer’s disease in population or clinic
based series or in familial disease. Neurosci Lett 2000;285:147–9.
8 Bullido MJ, Aldudo J, Frank A, et al. A polymorphism in the tau gene
associated with risk for Alzheimer’s disease. Neurosci Lett
2000;278:49–52.
9 Crawford F, Freeman M, Town T, et al. No genetic association between
polymorphisms in the Tau gene and Alzheimer’s disease in clinic or
population based samples. Neurosci Lett 1999;266:193–6.
10 Kwon JM, Nowotny P, Shah PK, et al. Tau polymorphisms are not
associated with Alzheimer’s disease. Neurosci Lett 2000;284:77–80.
11 Lilius L, Froelich Fabre S, Basun H, et al. Tau gene polymorphisms and
apolipoprotein E epsilon4 may interact to increase risk for Alzheimer’s
disease. Neurosci Lett 1999;277:29–32.
12 Roks G, Dermaut B, Heutink P, et al. Mutation screening of the tau gene
in patients with early-onset Alzheimer’s disease. Neurosci Lett
1999;277:137–9.
13 Russ C, Powell JF, Zhao J, et al. The microtubule associated protein Tau
gene and Alzheimer’s disease – an association study and meta-analysis.
Neurosci Lett 2001;314:92–6.
14 McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of
Alzheimer’s disease: report of the NINCDS-ADRDA work group under the
auspices of Department of Health and Human Services task force on
Alzheimer’s disease. Neurology 1984;34:939–44.
15 Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a
registry for Alzheimer’s disease (CERAD). Part I. Clinical and
neuropsychological assessment of Alzheimer’s disease. Neurology
1989;39:1159–65.
16 Bernard PS, Pritham GH, Wittwer CT. Color multiplexing hybridization
probes using the apolipoprotein E locus as a model system for
genotyping. Anal Biochem 1999;273:221–8.
17 Cook L, Brayne CE, Easton D, et al. No evidence for an association
between Saitohin Q7R polymorphism and Alzheimer’s disease. Ann
Neurol 2002;52:690–1.
18 Verpillat P, Ricard S, Hannequin D, et al. Is the Saitohin gene involved
in neurodegenerative diseases? Ann Neurol 2002;52:829–32.
Table 1 Analysis of 225 patients with Alzheimer’s disease and 144 healthy control
subjects
Diagnosis
Sample HCS (n (%)) AD (n (%)) Total
Swiss Genotype: A/A 55 (59.8) 53 (58.2) 108 (59.0)
A/G 35 (38.0) 31 (34.1) 66 (36.1)
G/G 2 (2.2) 7 (7.7) 9 (4.9)
Allele: A 145 (78.80) 137 (75.27) 282 (77.05)
G 39 (21.20) 45 (24.73) 84 (22.95)
Greek Genotype: A/A 29 (55.8) 91 (67.9) 120 (64.5)
A/G 21 (40.4) 37 (27.6) 58 (31.2)
G/G 2 (3.80) 6 (4.50) 8 (4.30)
Allele: A 79 (75.96) 219 (81.72) 298 (80.11)
G 25 (24.04) 49 (18.28) 74 (19.89)
Combined Genotype: A/A 84 (58.3) 144 (64.0) 228 (61.8)
A/G 56 (38.9) 68 (30.2) 124 (33.6)
G/G 4 (2.8) 13 (5.8) 17 (4.6)
Allele: A 224 (77.78) 356 (79.11) 580 (78.59)
G 64 (22.22) 94 (20.89) 158 (21.41)
The samples were age and sex matched. Mean (SD) age at diagnosis was 71.61 (6.9) years in the
Alzheimer’s disease group; age at examination in the control group was 70.0 (6.3) years. The samples came
from two white populations (Swiss/Greek).
There were no statistically significant associations between to STH genotypes or alleles and Alzheimer’s
disease in single or combined samples.
AD, Alzheimer’s disease; HCS, healthy control sample.
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